Filing Flows › Atrium Therapeutics (RNA) › Next earnings date
Atrium Therapeutics (RNA) earnings on Nov 9, 2026: what to expect
Atrium Therapeutics (RNA) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.63 (−$0.67 to −$0.59, 2 estimates) on revenue of $12.0M. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 68% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
The last report
Atrium Therapeutics reported revenue of $3.0M for the second quarter 2026 (-22% Y/Y), net loss $20.2M. How it makes money → · Every quarter →
Atrium Therapeutics' latest quarter
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
When does RNA report earnings?
Atrium Therapeutics is expected to report on Nov 9, 2026 (estimated).
What are analysts expecting from Atrium Therapeutics?
EPS of −$0.63 and revenue of $12.0M for the quarter.
Does Atrium Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 50% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.